[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619702":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"GR1803 injection dose 1","EXPERIMENTAL",null,[13],"Biological: GR1803 injection",{"label":15,"type":10,"description":11,"interventionNames":16},"GR1803 injection dose 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"GR1803 injection dose 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"GR1803 injection dose 4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"BIOLOGICAL","GR1803 injection","step-up dosing, Dose and frequency according to the protocol",[9,15,18,21],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Nian","CONTACT","021-50805989-08324","nianhanli@genrixbio.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430000","China","CN",{"type":45,"coordinates":46},"Point",[47,48],114.26667,30.58333,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":11,"email":11},"Professor Li","021-027-84397521",{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100619702","phase-1-a-study-of-gr1803-in-systemic-lupus-erythematosus-100619702",false,"NCT07348055","A Study of GR1803 in Systemic Lupus Erythematosus","A Phase Ib\u002FIIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* comfirmed diagnosis of systemic lupus erythematosus\n* SLEDAI-2K≥6分\n* written informed consent and ability to comply with protocol requirements\n* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months\n\nExclusion Criteria:\n\n* with unstable acute and chronic diseases\n* active infection\n* history of malignant tumor within 5 years","ALL","18 Years","60 Years",{"count":67,"type":68},44,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE1","PHASE2","to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus",[75,76],"Systemic Lupus Erthematosus","Auto Immune Disease",[78,79],"BCMA\u002FCD3 Bispecific Antibody","systemic lupus erythematosus","2026-03-09",{"date":82,"type":83},"2026-03-10","ACTUAL",{"date":85,"type":83},"2026-02-02",{"date":87,"type":68},"2027-12-01",{"name":5,"class":6},1]